Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/8/2020
SIETES contiene 93083 citas

 
 
 1 a 20 de 32 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Anónimo. Nivolumab successful in advanced stomach cancer trial. DIA Daily 2016:7. [Ref.ID 100921]
4. Cita con resumen
Pottegard A, Friis S, Andersen M, Hallas J. Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol 2013;75:1356-64. [Ref.ID 95330]
6. Cita con resumen
de Vries F. Bisphosphonates and cancer. One database, many answers. BMJ 2010;341:905. [Ref.ID 89578]
7.Tiene citas relacionadas Cita con resumen
Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satah T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang Y-K, for the ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97. [Ref.ID 89250]
8.Tiene citas relacionadas Cita con resumen
Munro AJ, Niblock PG. Cancer research in the global village. Lancet 2010;376:659-60. [Ref.ID 89243]
9.
Anónimo. Trastuzumab et cancers de l'estomac métastasés. Pour certains malades seulement. Drug Ther Bull 2007;45:732. [Ref.ID 89211]
10. Cita con resumen
The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer. A meta-analysis. JAMA 2010;303:1729-37. [Ref.ID 88403]
11.Tiene citas relacionadas Cita con resumen
Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 2009;151:121-8. [Ref.ID 86374]
12.Tiene citas relacionadas Cita con resumen
Wysowski DK. More on reports of esophageal cancer with oral phisphosphonate use. The author replies. N Engl J Med 2009;360:1791-2. [Ref.ID 85681]
13.Tiene citas relacionadas
Siris ES, Oster MW, Bilezikian JP. More on reports of esophageal cancer with oral phisphosphonate use. N Engl J Med 2009;360:1791. [Ref.ID 85680]
14.Tiene citas relacionadas Cita con resumen
Shaheen NJ. More on reports of esophageal cancer with oral phisphosphonate use. N Engl J Med 2009;360:1790-1. [Ref.ID 85679]
15.Tiene citas relacionadas
Robins HI, Holen KD. More on reports of esophageal cancer with oral phisphosphonate use. N Engl J Med 2009;360:1790. [Ref.ID 85678]
16.Tiene citas relacionadas Cita con resumen
Hofbauer LC, Miehlke S. More on reports of esophageal cancer with oral phisphosphonate use. N Engl J Med 2009;360:1790. [Ref.ID 85677]
17.Tiene citas relacionadas Cita con resumen
Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral phisphosphonate use. N Engl J Med 2009;360:1789-90. [Ref.ID 85676]
18.Tiene citas relacionadas Cita con resumen
Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral phisphosphonate use. N Engl J Med 2009;360:1789. [Ref.ID 85675]
19. Cita con resumen
Elwood PC, Gallagher AM, Duthie GG, Mur LAJ, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009;373:1301-9. [Ref.ID 85621]
20. Cita con resumen
Neuhouser ML, Wassertheil-Smoller S, Thomson C, Aragaki A, Anderson GL, Manson JE, Patterson RE, Rohan TE, Van Horn L, Shikany JM, Thomas A, Lacroix A, Prentice RL. Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. Arch Intern Med 2009;169:294-304. [Ref.ID 85262]
Seleccionar todas
 
 1 a 20 de 32 siguiente >>